Characteristic | N = 45 |
---|---|
Gender | |
Male/female | 33/12 |
Median age at chemoradiotherapy (years) | 71 (41–80) |
Median age at progressive disease (years) | 71 (42–82) |
Performance Status at progressive disease | |
0/1/2/3/4 | 15/22/4/4/0 |
Smoking history | |
Yes/No | 36/9 |
Histology | |
Adenocarcinoma/squamous cell carcinoma/others | 23/16/6 |
Clinical stage at diagnosis | |
IIIA/IIIB/IIIC | 28/14/3 |
Driver mutation/translocation | |
|
6/2/1/0/0/36 |
PD-L1 TPS | |
< 1% / 1–49% / 50%/unknown | 6/5/8/26 |
Progression-free survival (months) | . |
< 6 / 6 | 13/32 |
Overall response to chemoradiotherapy | |
CR/PR/SD/PD/NE | 0/26/15/4/0 |
Glasgow prognostic score (GPS) | |
0–1/2 | 32/13 |
Administration of tyrosine kinase inhibitors | |
Yes/No | 11/34 |
Administration of immune checkpoint inhibitors | |
Yes/No | 12/33 |
Administration of durvalmab | |
Yes/No | 2/43 |
Recurrent pattern | |
Local recurrence/distant metastasis | 17/28 |
Intracranial metastases at recurrence | |
Yes/No | 7/38 |
Liver metastases at recurrence | |
Yes/No | 3/42 |
Bone metastases at recurrence | |
Yes/No | 15/30 |
Oligorecurrrence | |
Yes/No | 11/34 |
Radiotherapy after recurrence (any site) | |
Yes/No | 19/26 |
Number of drug therapies after chemoradiotherapy | |
0/1/2/3/4 | 14/18/9/2/2 |
Median (range) | 1 |
Median (range) radiation dosage (Gy) | 60 (58–70) |
Chemotherapy regimen | |
CDDP + VNR | 1 |
CDDP + S-1 | 0 |
CBDCA + PTX | 30 |
Low dose CBDCA | 14 |
Median | Post-progression survival |
||||||
---|---|---|---|---|---|---|---|
PPS | Univariate analysis | Multivariate analysis | |||||
(months) | HR | 95% CI | HR | 95% CI | |||
Gender | |||||||
Male/female | 18.1/25.7 | 1.49 | 0.63–4.07 | 0.37 | |||
Age at recurrence (years) | |||||||
< 75 / 75 | 20.0/19.5 | 0.78 | 0.36–1.77 | 0.54 | |||
PS at recurrence | |||||||
0–1 / 2 | 21.3/2.8 | 0.42 | 0.18–1.09 | 0.07 | |||
Smoking history | |||||||
Yes/No | 16.7/25.7 | 1.87 | 0.71–6.39 | 0.21 | |||
Histology | |||||||
Adenocarcinoma/non-adenocarcinoma | 25.7/10.5 | 0.37 | 0.17–0.79 | 1.06 | 0.36–3.04 | 0.90 | |
Driver mutation/translocation | |||||||
Yes/No | 27.3/15.1 | 0.32 | 0.07–0.95 | 0.61 | 0.13–2.23 | 0.47 | |
Best overall response of chemoradiotherapy | |||||||
PR/non-PR | 15.1/22.1 | 1.82 | 0.86–4.11 | 0.11 | |||
Progression-free survival | |||||||
< 6 months / 6 months | 6.4 / 24.4 | 1.97 | 0.89–4.19 | 0.09 | |||
Glasgow prognostic score (GPS) at recurrence | |||||||
0–1/2 | 25.7/6.7 | 0.23 | 0.11–0.52 | 0.2 | 0.06–0.55 | ||
Recurrence pattern | |||||||
Local recurrence/distant metastasis | 40.7/16.7 | 0.45 | 0.18–1.03 | 0.05 | |||
Intracranial metastases at recurrence | |||||||
Yes/No | 6.7/21.3 | 1.75 | 0.64–4.09 | 0.25 | |||
Liver metastases at recurrence | |||||||
Yes/No | 4.2/21.3 | 6.82 | 1.50–22.8 | 12.7 | 2.40–56.8 | ||
Bone metastases at recurrence | |||||||
Yes/No | 18.1/20.0 | 1.40 | 0.60–3.06 | 0.41 | |||
Oligorecurrence at recurrence | |||||||
Yes/No | 22.1/19.2 | 0.77 | 0.30–1.75 | 0.55 |
first-line | second-line | third-line | ≧fourth-line | Total | |
---|---|---|---|---|---|
Platinum combination | 11 | 3 | 2 | 0 | 16 |
Platinum combination + ICIs | 0 | 0 | 0 | 0 | 0 |
Docetaxel | 0 | 4 | 2 | 0 | 6 |
Docetaxel+ ramcirumab | 0 | 0 | 0 | 0 | 0 |
Pemetrexed | 0 | 0 | 2 | 0 | 2 |
S1 | 1 | 0 | 0 | 3 | 4 |
Others (single agents) | 0 | 1 | 0 | 0 | 1 |
EGFR-TKIs | 6 | 1 | 0 | 0 | 7 |
ALK-TKIs | 3 | 1 | 0 | 0 | 4 |
ICI monotherapy | 1 | 5 | 2 | 1 | 9 |
Ipilimumab+nivolumab | 1 | 0 | 0 | 0 | 1 |
Investigational agents | 0 | 0 | 0 | 0 | 0 |
Radiotherapy alone | 12 | 1 | 0 | 0 | 13 |
Best supportive care | 10 | - | - | - | 10 |